Barr/Enhance Acquisition’s First Product Expected To Be Oxybutynin Ring

Barr's first product to market from its acquisition of Enhance Pharmaceuticals is expected to be a vaginal ring for the treatment of urinary incontinence

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet